Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Shenzhen Bioeasy Biotechnology Co., Ltd. specializes in the development and production of rapid diagnostic tests and medical devices, primarily focusing on infectious diseases and chronic conditions. The company has a strong competitive position in the Chinese market, leveraging its advanced R&D capabilities and a diverse product portfolio that includes over 100 types of diagnostic kits.
The company generates revenue primarily through the sale of its diagnostic kits, which are priced competitively due to their high accuracy and speed. Bioeasy benefits from strong relationships with hospitals and clinics in China, providing a steady demand for its products. Its ability to innovate and adapt to regulatory changes gives it a competitive edge.
Regulatory approvals for new diagnostic tests
Changes in healthcare policies affecting diagnostic testing
Market demand for rapid testing solutions, especially during health crises
Partnerships or collaborations with larger healthcare firms
Regulatory changes that could impact the approval process for new products
Technological disruption from competitors developing more advanced diagnostic solutions
Increased competition from both domestic and international biotech firms
Potential market saturation in the rapid testing segment
Low return on equity (0.8%) indicating potential inefficiencies in capital utilization
Operating margin of only 2.1% raises concerns about profitability under competitive pricing pressure
moderate - while healthcare spending is generally resilient, demand for diagnostic tests can fluctuate with economic conditions and public health crises.
The company has a moderate sensitivity to interest rates as higher rates could increase financing costs for R&D and expansion efforts, potentially impacting growth.
minimal - the company has a manageable debt-to-equity ratio of 0.50, indicating limited reliance on external financing.
growth - investors are likely attracted to the company's potential for rapid expansion in the biotech sector.
high - the stock has experienced significant volatility with a 1-year return of -35.9%, indicating potential for large price swings.
